Week In Review: Nikang Raises $200 Million From US And China Investors

Dna, Genetic Material, Helix, Proteins, Biology

Image Source: Unsplash

Deals and Financings

  • NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors (see story). NiKang was originally incubated by CBC Group (C-Bridge Capital) in 2017. It focuses on innovative small molecule oncology medicines that are discovered based on target structure biology and using structure-based drug design. The company believes its strategy speeds the process and offers better pharmacological candidates. The C round was led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors.  
  • Esco Lifesciences of Singapore, an Asia-based life sciences tools company, closed an over-subscribed $200 million Series A and crossover round (see story). The financing will support strategic bolt-on M&A acquisitions and expedited expansion in China, the company's primary and fastest-growing market. Esco also intends to expand its cell and gene therapy tools and technologies portfolio, together with an innovation hub in Boston. The A round was led by Vivo Capital and Novo Holdings A/S. 

Trials and Approvals 

1 2
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.